On September 3, 2024, EyePoint Pharmaceuticals, Inc. announced significant changes to its Board of Directors. Dr. David R. Guyer and Dr. Anthony P. Adamis resigned from the Board and all committees due to their new full-time roles at Merck & Co. Their departures were not due to any disagreements with the company's operations, policies, or practices. Concurrently, the Board reduced its size from nine to eight members and appointed Fred Hassan to fill the vacancy. Hassan, a distinguished industry leader with a history of executive roles in pharmaceutical companies, received an initial grant of an option to acquire 60,000 shares of common stock, vesting over three years. His compensation aligns with the company's non-employee director policy. Additionally, Karen Zaderej and...Show More

On September 3, 2024, EyePoint Pharmaceuticals, Inc. announced significant changes to its Board of Directors. Dr. David R. Guyer and Dr. Anthony P. Adamis resigned from the Board and all committees due to their new full-time roles at Merck & Co. Their departures were not due to any disagreements with the company's operations, policies, or practices. Concurrently, the Board reduced its size from nine to eight members and appointed Fred Hassan to fill the vacancy. Hassan, a distinguished industry leader with a history of executive roles in pharmaceutical companies, received an initial grant of an option to acquire 60,000 shares of common stock, vesting over three years. His compensation aligns with the company's non-employee director policy. Additionally, Karen Zaderej and Stuart Duty were appointed to the Compensation Committee, Nancy S. Lurker to the Science Committee, and Hassan to the Governance and Nominating Committee. The company also entered into an indemnification agreement with Hassan. On September 4, 2024, a press release was issued to announce these Board changes. EyePoint Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing treatments for serious retinal diseases, with its lead product candidate, DURAVYU™, expected to enter Phase 3 clinical trials in 2024.